Loading clinical trials...
Loading clinical trials...
A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis
Conditions
Interventions
Deucravacitinb
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
November 21, 2025
Primary Completion Date
November 21, 2025
Completion Date
November 21, 2025
Last Updated
November 24, 2025
NCT00017914
NCT07089121
NCT04402086
NCT07160205
NCT07374107
NCT06479863
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions